Why Shares of Rocket Lab Lifted Off Today
Rocket Lab is a leading launch services provider.
Bank of America has upwardly revised its price target due, in part, to the potential of the company's Neutron rocket.
Because it's an unprofitable company, investors should only consider Rocket Lab if they're comfortable with a higher-risk investment.
10 stocks we like better than Rocket Lab ›
Each day this week, shares of Rocket Lab (NASDAQ: RKLB) have closed higher than where they ended the previous day's trading session. The trend doesn't show signs of stopping today. With an analyst's positive outlook for Rocket Lab stock, investors are continuing to click the buy button on the launch services provider.
As of 2:06 p.m. ET, shares of Rocket Lab are up 10.6%.
Development of a new rocket has this analyst optimistic
Maintaining its buy rating, Bank of America hiked its price target on Rocket Lab stock to $50 from $30. According to The Fly, the more auspicious view of the space stock is predicated on the favorable outlook for the Neutron rocket as well as the company's strength in satellite development position will provide more diverse offerings to customers.
Unlike its current rocket, Electron, the Neutron rocket is capable of larger payloads, and management is looking to its development as a major engine of growth for the company.
In March, Rocket Lab announced that the United States Space Force has chosen the Neutron rocket to compete for contracts from the National Security Space Launch program, which has a five-year ordering period that extends through June 2029 and has a maximum value of $5.6 billion.
Rocket Lab expects the first launch of Neutron to occur in the second half of 2025.
What's a potential Rocket Lab investor to do now?
It's important for those weighing an investment in Rocket Lab to remember that analysts often have shorter investing horizons than the long-term holding periods many investors favor. News of the higher price target, therefore, should be of little consequence. Instead, the company's robust backlog and progress with the Neutron program provide more concrete factors that can support an investment.
Of course, since the company is still unprofitable, only investors comfortable with a more speculative investment will want to consider Rocket Lab at this point. Fortunately, there are other space stocks to consider if Rocket Lab is deemed too speculative.
Should you invest $1,000 in Rocket Lab right now?
Before you buy stock in Rocket Lab, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,281!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,415!*
Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025
New York, New York--(Newsfile Corp. - July 30, 2025) - If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between September 17, 2024 and May 26, 2025. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. WHAT'S NEXT? If you suffered a loss in Rocket stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Globe and Mail
8 minutes ago
- Globe and Mail
StoneX Group Inc. to Announce 2025 Fiscal Third Quarter Earnings on August 5, 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- StoneX Group Inc. (NASDAQ: SNEX) today announced that it will release its fiscal 2025 third quarter results after the market close on Tuesday, August 5, 2025. Management will host a conference call on Wednesday, August 6, 2025 at 9:00 a.m. Eastern Time to review the Company's 2025 fiscal third quarter results. A live web cast of the conference call as well as additional information to review during the call will be made available in PDF form at Participants can also access the call via approximately ten minutes prior to the start time. Participants may preregister for the conference call here. For those who cannot access the live broadcast, a replay of the call will be available at About StoneX Group Inc. StoneX Group Inc., through its subsidiaries, operates a global financial services network that connects companies, organizations, traders and investors to the global market ecosystem through a unique blend of digital platforms, end-to-end clearing and execution services, high touch service and deep expertise. The Company strives to be the one trusted partner to its clients, providing its network, product and services to allow them to pursue trading opportunities, manage their market risks, make investments and improve their business performance. A Fortune-500 company headquartered in New York City and listed on the Nasdaq Global Select Market (NASDAQ:SNEX), StoneX Group Inc. and its more than 4,700 employees serve more than 54,000 commercial, institutional, and global payments clients, and more than 400,000 self-directed/retail accounts, from more than 80 offices spread across six continents. Further information on the Company is available at CONTACT: StoneX Group Inc. Investor Inquiries:
Globe and Mail
8 minutes ago
- Globe and Mail
Will Arista Networks Stock Keep Soaring as Q2 Earnings Approach?
Arista Networks ANET has joined a wave of tech stocks that are receiving upgrades from analysts thanks to its AI-driven data center innovation and robust revenue growth. Considering such, there is much enthusiasm building ahead of Arista Networks' Q2 report next Tuesday, August 5. To that point, Arista Networks' stock has rebounded more than +30% in the last three months and is now less than 10% from its all-time peak of $133 a share (stock-split adjusted basis), which it hit in January. Arista Networks Q2 Expectations As a brief preview, Arista Networks' Q2 sales are thought to have spiked 25% to $2.11 billion from $1.69 billion a year ago. Even better, Q2 earnings are also expected to be up 25% to $0.65 per share compared to EPS of $0.52 in the prior period. Adding to the enthusiasm for Arista Networks' Q2 report is that the cloud networking solutions leader has topped sales estimates for 22 consecutive quarters and has reached or exceeded the Zacks EPS Consensus in every quarter since 2014. Over the last four quarters, Arista Networks has posted an average sales and earnings surprise of 2.61% and 11.82% respectively. Arista Networks' Robust Revenue Growth Piggybacking on analysts upgrading Arista Networks' stock due to its robust revenue growth, the company's top line is now expected to expand 19% this year and is projected to stretch another 17% in fiscal 2026 to $9.76 billion. Since the pandemic, Arista Networks' top line has expanded more than 200% with 2020 sales at $2.31 billion. The remarkable post-pandemic surge has been fueled by major cloud players like Microsoft MSFT and Alphabet GOOGL, which rely heavily on Arista Networks' tailor-made AI data center networking platforms. EPS Outlook & Revisions Taking advantage of its sales growth, Arista Networks' bottom line is currently slated to expand 13% in FY25 with FY26 earnings forecasted to pop another 15% to $2.97 per share. Reassuringly, FY25 and FY26 EPS estimates have continued to trend higher over the last 90 days, moving slightly higher in the last month. Bottom Line Attributed to the trend of positive earnings estimate revisions, Arista Networks' stock lands a Zacks Rank #1 (Strong Buy) and could certainly be in store for more upside as its Q2 results approach next week. As a reminder that Arista Networks' stock previously traded over $400 a share prior to its 4-1 stock split last year, now appears to be an ideal time to buy ANET before it gets more expensive. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Arista Networks, Inc. (ANET): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
